Open AccessEGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy
Author(s) -
Zixuan Ye,
Yue Zhang,
Yuanfen Liu,
Yanyan Liu,
Jiasheng Tu,
Yan Shen
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s289228
Subject(s) - bovine serum albumin , cetuximab , doxorubicin , medicine , colorectal cancer , albumin , pharmacology , chemistry , cancer research , chemotherapy , cancer , immunology
Specific modifications to carriers to achieve targeted delivery of chemotherapeutics into malignant tissues are a critical point for efficient diagnosis and therapy. In this case, bovine serum albumin (BSA) was conjugated with cetuximab-valine-citrulline (vc)-doxorubicin (DOX) to target epidermal growth factor receptor (EGFR) and enable the release of drug in EGFR-overexpressed tumor cells.